ID: ALA131111

Max Phase: Preclinical

Molecular Formula: C25H27N3O3

Molecular Weight: 417.51

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1CC1=C(Nc2ccc(C3=NNC(=O)CC3C)cc2)CCCC1=O

Standard InChI:  InChI=1S/C25H27N3O3/c1-16-14-24(30)27-28-25(16)17-10-12-19(13-11-17)26-21-7-5-8-22(29)20(21)15-18-6-3-4-9-23(18)31-2/h3-4,6,9-13,16,26H,5,7-8,14-15H2,1-2H3,(H,27,30)

Standard InChI Key:  COEVDPWUZRPZIC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.51

Molecular Weight (Monoisotopic): 417.2052

AlogP: 4.22

#Rotatable Bonds: 6

Polar Surface Area: 79.79

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.79

CX Basic pKa: 3.07

CX LogP: 3.48

CX LogD: 3.48

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.74

Np Likeness Score: -0.39

References

1. Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S, MacIntyre E, Metzger J, O'Connor N, Patel K, Tong X, Tota MR, Van der Ploeg LH, Varnerin JP, Fisher MH, Wyvratt MJ, Weber AE, Parmee ER..  (2003)  Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.,  13  (22): [PMID:14592490] [10.1016/j.bmcl.2003.08.056]

Source

Source(1):

• Scientific Literature